IBD (Inflammatory Bowel Disease) is a common primary gastrointestinal (GI) disease causing undesired symptoms such as poor appetite, vomiting, and diarrhea in dogs.  Dogs that do not respond to diet and antibiotic therapies are treated with corticosteroid medications that can have side effects that can make quality of life worse in some cases. Therefore, more targeted immunotherapies are needed to inhibit the inflammation seen with this disease.

GLS-1027 has been shown to inhibit the inflammatory effects of a small population of white blood cells (Th17-mediated inflammation), which have shown to contribute to inflammatory bowel diseases in mice and people. In this study we are assessing the effect of GLS-1027 in dogs with chronic GI symptoms that do not respond to food or antibiotics with lab work routinely measured in the Loftus Laboratory and clinical setting at Cornell University Hospital for Animals.  Dogs will be randomly assigned to one of two groups: (1) standard of care dose of steroids + placebo, (2) half dose of standard of care steroids + low dose GLS-1027.

Eligibility: Dogs seen by the Cornell University Hospital for Animals who have been diagnosed with chronic enteropathy (symptoms for >3 weeks) who have already failed diet and antibiotic therapy, have had compatible diagnostics done to rule out other endocrine, infectious, or neoplastic causes, and have a biopsy diagnosis consistent with inflammatory bowel disease. Dogs must be >5kg. Dogs with a history of corticosteroid or other immunosuppressive treatment of more than 10 days in the preceding month may not participate.

Compensation: The drug or placebo will be provided for free. Additionally, you will receive some free lab work at days 14 and 28. There will be a 10% hospital discount on all study-related visits.

Owner Responsibilities: This is a 28-day study. You are responsible for administering study medications as directed and must return your dog to CUHA for follow-up appointments around day 14 and day 28. You will be asked to fill out a one-page journal to document drug administration and any change in symptoms.

Principal Investigator: Jennifer Prieto, DVM, DACVIM

Contact/Schedule an Appointment: If you have a dog you think may be eligible please call the internal medicine service or the clinical trials coordinator at 607.253.3060, or email vet-research@cornell.edu